Form 8-K - Current report:
SEC Accession No. 0001213900-22-076435
Filing Date
2022-11-30
Accepted
2022-11-30 17:00:24
Documents
14
Period of Report
2022-11-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea169426-8k_180lifesci.htm   iXBRL 8-K 34835
2 PRESS RELEASE DATED NOVEMBER 30, 2022 ea169426ex99-1_180lifesci.htm EX-99.1 14703
  Complete submission text file 0001213900-22-076435.txt   277677

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE atnf-20221130.xsd EX-101.SCH 3992
4 XBRL DEFINITION FILE atnf-20221130_def.xml EX-101.DEF 26629
5 XBRL LABEL FILE atnf-20221130_lab.xml EX-101.LAB 36680
6 XBRL PRESENTATION FILE atnf-20221130_pre.xml EX-101.PRE 25253
8 EXTRACTED XBRL INSTANCE DOCUMENT ea169426-8k_180lifesci_htm.xml XML 5685
Mailing Address 3000 EL CAMINO REAL BLDG 4, STE 200 PALO ALTO CA 94306
Business Address 3000 EL CAMINO REAL BLDG 4, STE 200 PALO ALTO CA 94306 650-507-0669
180 Life Sciences Corp. (Filer) CIK: 0001690080 (see all company filings)

EIN.: 813832378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38105 | Film No.: 221436166
SIC: 2834 Pharmaceutical Preparations